Want to see SYK full AI Analyst Report?
Top Page
Stryker
(NYSE:SYK)
Select Model
Select Model
Rating:70Outperform
Price Target:
$304.00
▼(-7.79% Downside)
Action:Reiterated
Date:09/09/26
Overall score reflects strong underlying financial performance and a positive guidance/sentiment backdrop from the latest earnings call, partly offset by very weak current technical momentum (oversold and below all key moving averages) and a premium valuation (P/E ~28) with only a modest dividend yield.
Positive Factors
Strong organic growth and expanding margins
Broad-based organic growth paired with double-digit adjusted EPS expansion indicates strong demand and operating leverage. Higher gross and operating margins can support reinvestment, innovation, and earnings durability, while 2026 guidance preserves a high-single-digit growth outlook.
Negative Factors
Peripheral vascular supply disruption
The disruption demonstrates that operational issues within a key product line can directly reduce sales and delay procedures. Even with management expecting manageable backorders by the end of Q3, recovery timing and lost customer activity may weigh on results over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong organic growth and expanding margins
Broad-based organic growth paired with double-digit adjusted EPS expansion indicates strong demand and operating leverage. Higher gross and operating margins can support reinvestment, innovation, and earnings durability, while 2026 guidance preserves a high-single-digit growth outlook.
Read all positive factors
Stryker Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down Stryker’s revenue by region to show geographic concentration, sensitivity to local healthcare spending and procedure volumes, and which markets are fueling future expansion or posing risk.
Breaks down Stryker’s revenue by region to show geographic concentration, sensitivity to local healthcare spending and procedure volumes, and which markets are fueling future expansion or posing risk.
Data provided by:
The Fly
The FlyStryker (SYK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$106.93B
Dividend Yield1.28%
Average Volume (3M)2.76M
Price to Earnings (P/E)28.3
Beta (1Y)0.60
Revenue Growth8.48%
EPS Growth27.36%
CountryUS
Employees56,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)9.73
Shares Outstanding383,573,060
10 Day Avg. Volume2,828,097
30 Day Avg. Volume2,758,576
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$367.84Price Target Upside11.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)14.99
Revenue Forecast (FY)$27.23B
Stryker Business Overview & Revenue Model
Company Description
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including ...
How the Company Makes Money
Stryker makes money primarily by selling medical devices, implants, capital equipment, and related consumables and services to hospitals, surgery centers, and other healthcare providers globally. Its revenue model combines: (1) recurring procedure...
Stryker Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed broad recovery and operational momentum: solid organic growth (9%), a strong adjusted EPS beat (+17.9%), expanding margins, record Mako performance, multiple product launches and healthy cash generation/backlog. Key negatives were an acute supply disruption in peripheral vascular (Inari) that drove a U.S. vascular decline (‑6.7%), lingering costs and absorption effects from the prior cybersecurity incident, and some launch timing variability. Management expects backorders to be manageable by end of Q3 and reiterated confidence in the full‑year outlook and capital demand, so positives materially outweigh manageable near‑term headwinds.Positive Updates
Strong overall organic sales growth
Company delivered 9% organic sales growth in Q2 2026 (9% U.S., ~8.9% international). Management narrowed full‑year organic net sales guidance to 8.3%–9.3%.
Negative Updates
Peripheral vascular (Inari) supply disruption and lost sales
U.S. vascular organic sales declined 6.7% in Q2 due to an operational disruption at an Inari plant that created meaningful backorders and lost sales. Management expects backorders to reach a manageable level by end of Q3. Analysts on the call estimated the drag to be roughly in the ~50–75 basis point range, and management said that estimate was 'in the ballpark.'
Read all updates
Q2-2026 Updates
Positive
Negative
Strong overall organic sales growth
Company delivered 9% organic sales growth in Q2 2026 (9% U.S., ~8.9% international). Management narrowed full‑year organic net sales guidance to 8.3%–9.3%.
Read all positive updates
Company Guidance
Stryker narrowed 2026 guidance to organic net sales growth of 8.3%–9.3% and adjusted net EPS of $14.95–$15.10 (with a modestly positive pricing impact and a slight FX tailwind if rates hold), after reporting Q2 organic sales growth of 9% and adjusted EPS of $3.69 (up $0.56, +17.9%); Q2 adjusted gross margin was 66% (+60 bps) and adjusted operating margin 27.4% (+170 bps). Management expects full‑year adjusted other income/expense of ≈$420M, a full‑year effective tax rate of 15%–16% (Q2: 16.5%), cash & marketable securities of ≈$3.5B and year‑to‑date cash from operations of $1.8B, and said peripheral vascular backorders should be manageable by end‑Q3. They reiterated confidence in a strong second half driven by elevated capital demand and production ramp, plan to resume share repurchases (≈$1B previously authorized) while keeping M&A the primary capital allocation priority.Stryker Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
74
Positive
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.84B | 25.12B | 22.59B | 20.50B | 18.45B | 17.11B |
| Gross Profit | 16.84B | 16.07B | 13.98B | 12.49B | 11.04B | 10.71B |
| EBITDA | 6.25B | 6.31B | 4.94B | 5.06B | 4.02B | 3.61B |
| Net Income | 3.73B | 3.25B | 2.99B | 3.17B | 2.36B | 1.99B |
Balance Sheet | ||||||
| Total Assets | 47.93B | 47.84B | 42.97B | 39.91B | 36.88B | 34.63B |
| Cash, Cash Equivalents and Short-Term Investments | 3.48B | 4.10B | 4.49B | 3.05B | 1.93B | 3.02B |
| Total Debt | 14.94B | 16.36B | 14.12B | 13.49B | 13.53B | 12.90B |
| Total Liabilities | 23.94B | 25.42B | 22.34B | 21.32B | 20.27B | 19.75B |
| Stockholders Equity | 23.99B | 22.42B | 20.63B | 18.59B | 16.62B | 14.88B |
Cash Flow | ||||||
| Free Cash Flow | 4.70B | 4.28B | 3.49B | 3.14B | 2.04B | 2.74B |
| Operating Cash Flow | 5.53B | 5.04B | 4.24B | 3.71B | 2.62B | 3.26B |
| Investing Cash Flow | -1.45B | -4.87B | -3.00B | -962.00M | -2.92B | -859.00M |
| Financing Cash Flow | -3.04B | 113.00M | -525.00M | -1.59B | -749.00M | -2.37B |
Stryker Technical Analysis
Negative
329.67
Price Trends
311.84
Negative
311.14
Negative
328.95
Negative
Market Momentum
-11.05
Negative
37.40
Neutral
45.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYK, the sentiment is Negative. The current price of 329.67 is above the 20-day moving average (MA) of 280.07, above the 50-day MA of 311.84, and above the 200-day MA of 328.95, indicating a bearish trend. The MACD of -11.05 indicates Negative momentum. The RSI at 37.40 is Neutral, neither overbought nor oversold. The STOCH value of 45.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SYK.
Stryker Risk Analysis
Stryker disclosed 29 risk factors in its most recent earnings report. Stryker reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stryker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $10.16B | 18.87 | 11.59% | ― | 19.74% | 51.10% | |
77 Outperform | $111.40B | 21.10 | 10.60% | 3.31% | 9.77% | 12.28% | |
71 Outperform | $11.23B | 17.61 | 12.25% | 2.90% | 5.26% | 31.02% | |
71 Outperform | $17.42B | 21.52 | 6.36% | 1.08% | 8.62% | 0.09% | |
70 Outperform | $106.93B | 28.32 | 16.36% | 1.28% | 8.48% | 27.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.29B | -176.57 | -0.69% | ― | 1.60% | 98.56% |
* Healthcare Sector Average
SYK
Stryker
275.39
-87.00
-24.01%
IART
Integra Lifesciences
16.28
2.31
16.54%
MDT
Medtronic
86.29
-6.13
-6.63%
SNN
Smith & Nephew Snats
26.96
-8.68
-24.36%
ZBH
Zimmer Biomet Holdings
88.83
-9.29
-9.47%
GMED
Globus Medical
74.90
16.84
29.00%
Stryker Corporate Events
Business Operations and StrategyDividendsFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Stryker Reorganizes Orthopaedics Into New Ortho Tech Business
Positive
Jun 26, 2026
In the first quarter of 2026, Stryker reorganized its Orthopaedics operations by creating an Ortho Tech business that combines orthopaedic instruments from its Instruments unit with the Mako robotics and enabling technologies portfolio, aiming to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.